Document Detail

Combination of cyclophosphamide, etoposide, carboplatin and dexamethasone as a salvage regimen for refractory multiple myeloma patients: a comparison with a historical control group.
MedLine Citation:
PMID:  23087803     Owner:  NLM     Status:  PubMed-not-MEDLINE    
The aim of this study was to design a regimen for refractory multiple myeloma with minimum complications to achieve a reasonable response. Fifteen patients with active multiple myeloma after at least two lines of conventional treatment underwent therapy with our regimen for two cycles. Disease activity was evaluated after the last cycle. Another 15 patients with refractory multiple myelomas that had previously received only supportive therapy and pain management formed a historical control group. The follow-up period was 12 months for each study group. Of the patients receiving therapy, 6.7% achieved a complete response and 26.7% a partial response; overall response rate was 33.3%. Stable disease was achieved in 46.7% and 20% of the patients had progressive disease. There was no treatment related mortality. The hazard rate of death was 0.73 lower in the intervention group than in the historical control group. In the historical control group, 60% had progressive disease and 40% had stable disease; approximately 40% of patients died during the 12-month follow up. Also, the severity of pain was significantly reduced in the intervention group (P=0.033). Our chemotherapy regimen showed a reasonable response in end stage patients with multiple myeloma in terms of disease control, reducing bone pain and improving survival, in addition to reducing toxicity.
Reza Safaee; Ahmad Ahmadzadeh; Ramezanali Sharifian; Amirhossein Emami; Mir Saeed Yekaninejad; Mohammad Hossein Jalili; Armita Valizadeh
Related Documents :
23240903 - Higher incidence of injection site reactions after subcutaneous bortezomib administrati...
24009143 - Quantification of airflow into the maxillary sinuses before and after functional endosc...
22525883 - Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolon...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hematology reports     Volume:  4     ISSN:  2038-8330     ISO Abbreviation:  Hematol Rep     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-10-22     Completed Date:  2012-10-23     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101556723     Medline TA:  Hematol Rep     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  e14     Citation Subset:  -    
Hematology and Oncology Research Center, Vali-Asr Hospital and.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Giant cell temporal arteritis associated with overlying basal cell carcinoma: co-incidence or connec...
Next Document:  B-cell acute lymphoblastic leukemia with t(4;11)(q21;q23) in a young woman: evolution into mixed phe...